ANNUAL REPORT
Download the full report, individual sections or visit iXBRL viewer
2024 provided further evidence that Emma and her executive team have seized the opportunity of the demerger to make fundamental improvements to GSK’s operational performance, competitiveness and pipeline.
We have delivered sustained year-on-year sharper operational performance, profitability and cash improvements. And our long-term outlooks have consistently improved, alongside the quality of our R&D innovation.
2024 performance and key performance indicators
We delivered another year of excellent performance in 2024, with strong sales and core operating profit growth driven by accelerating momentum of our specialty medicines portfolio.
Research and development
We continued to strengthen our late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth.
Responsible business
We are committed to getting ahead of issues that matter for society and for the long-term performance of our company.
Our Responsible Business Performance Rating tracks progress across our six focus areas: access; global health and health security; environment; inclusion; ethical standards; and product governance.
Culture and people
People are at the heart of our success. We are committed to making GSK a place where people can thrive, with a culture where we are all ambitious for patients, accountable for impact, and do the right thing. This means we support our people to do things better and faster, focusing on what matters most. We measure progress on embedding our culture through our employee surveys.
-
Our employee engagement score in 2024 remained high:
81%
